Rankings / Muscle & Strength

Tesamorelin

Muscle & Strength · Stabilized GHRH analog

Tier B-

gh-axisprescription
5.8 / 10
Tier B-
Ev 8 Bn 5 Sf 3.5

Bottom line

Read Off Label grades Tesamorelin as B- (5.8/10) based on strong evidence, med benefit magnitude, and a med-high-risk safety profile.

Only FDA-approved GHRH analog for metabolic indication.

Typical use: 1. — Rx (Egrifta/Egrifta SV) for HIV lipodystrophy; off-label for visceral fat reduction.

What this is

Only FDA-approved GHRH analog for metabolic indication. Stanley 2014 NEJM showed liver fat reduction in HIV patients with NAFLD. Notable worsening of insulin sensitivity limits cohort applicability. Expensive at list price; becoming more common in off-label metabolic/longevity prescribing.

Mechanism

Synthetic trans-3-hexenoic acid-modified GHRH(1-44); FDA-approved (Egrifta) 2010 for HIV-associated lipodystrophy; reduces visceral adipose tissue

Dose & route

1.4 mg (Egrifta SV) or 2 mg (Egrifta) subQ daily

Common questions

Does Tesamorelin work?
Read Off Label rates the evidence for Tesamorelin as Strong and the benefit magnitude as med, producing an overall grade of B- (5.8/10). Only FDA-approved GHRH analog for metabolic indication.
Is Tesamorelin safe?
Tesamorelin has a med-high risk profile in published human data. Legal status: Rx (Egrifta/Egrifta SV) for HIV lipodystrophy; off-label for visceral fat reduction. This is not medical advice — see the disclaimer.
What is the typical dose for Tesamorelin?
1.4 mg (Egrifta SV) or 2 mg (Egrifta) subQ daily
How does Tesamorelin work?
Synthetic trans-3-hexenoic acid-modified GHRH(1-44); FDA-approved (Egrifta) 2010 for HIV-associated lipodystrophy; reduces visceral adipose tissue

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.